Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Keytruda resistance shown as a monotherapy in anal cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 25, 2024 10:18pm

111 Views

Post# 35952099

RE:RE:RE:Keytruda resistance shown as a monotherapy in anal cancer

In a Nov. 9, 2023 press release— Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA) by Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg,

The GOBLET anal cohort demonstrated: Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?